Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy

By sjmartinez • June 3, 2024

Miller JE, Taylor-Cousar JL, Overdevest JB, Khatiwada A, Mace JC, Alt JA, Bodner TE, Chowdhury NI, DiMango EA, Eshaghian PH, Getz AE, Gudis DA, Han EJ, Hwang PH, Keating CL, Khanwalkar A, Kimple AJ, Lee JT, Li D, Markarian K, Norris M, Nayak JV, Owens C, Patel ZM, Poch K, Schlosser RJ, Smith KA, Smith TL, Soler ZM, Suh JD, Tervo JP, Turner GA, Wang MB, Saavedra MT, Beswick DM. Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy. Int Forum Allergy Rhinol. 2024 Jun;14(6):1079-1087. doi: 10.1002/alr.23312. Epub 2023 Dec 25. PMID: 38145393.

Tags: chronic rhinosinusitis, cystic fibrosis, highly effective modulator therapy, olfaction, olfactory disorders, olfactory dysfunction, olfactory test, patient‐reported outcome measure, Publications, Pulmonary, Critical Care & Sleep Medicine, Quality of Life

Stroke Rehabilitation: Synopsis of the 2024 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines

Eapen BC, Tran J, Ballard-Hernandez J, Buelt A, Hoppes CW, Matthews C, Pundik S, Reston J, Tchopev Z, Wayman LM, Koehn T. Stroke Rehabilitation: Synopsis[...]

Pregnancy Complications and Long-Term Atherosclerotic Cardiovascular Disease Risk

Rabadia SV, Heimberger S, Cameron NA, Shahandeh N. Pregnancy Complications and Long-Term Atherosclerotic Cardiovascular Disease Risk. Curr Atheroscler Rep. 2025 Jan 20;27(1):27. doi: 10.1007/s11883-024-01273-9. PMID:[...]

Introducing the PROMIS-16 profile 1.0

Edelen MO, Hays RD, Herman PM. Introducing the PROMIS-16 profile 1.0. Qual Life Res. 2025 Jan 20. doi: 10.1007/s11136-024-03885-9. Epub ahead of print. PMID: 39831935.